Navigation Links
For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
Date:9/23/2010

BURLINGTON, Mass., Sept. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of multiple myeloma, more surveyed European hematologist-oncologists consider the combination of immunomodulatory agents and proteasome inhibitors promising with respect to efficacy than is the case for any other drug regimen combinations. In light of these findings, the emerging regimen of Onyx Pharmaceuticals' carfilzomib in combination with Celgene's Revlimid has the potential to be the most efficacious strategy for multiple myeloma treatment.

The new European Physician & Payer Forum report entitled European Physician and Payer Perspectives in Myeloma: How Will Emerging Therapies Compete With Well-Entrenched Brands? explores the future market dynamics for this indication in light of several highly-promising emerging agents in multiple myeloma. Although other agents are frequently used to treat the indication, Revlimid, Janssen-Cilag's Velcade and Celgene's Thalidomide together captured more than 80 percent of the multiple myeloma market in 2008 in France, Germany, Italy, Spain and the United Kingdom (EU5).

"Most surveyed European hematologist-oncologists indicate that Velcade is commonly used in the first-line setting while Revlimid-based regimens are more commonly used in the second- and third-line," said Decision Resources Analyst Andrew Merron, Ph.D. "Emerging agents such as carfilzomib are expected to enter the relapsed/refractory settings and will be used either in combination with Revlimid, Velcade and Thalidomide or they will compete directly with these agents. Other key agents in late stage development include Celgene's pomalidomide, AEterna Zentaris/Keryx Biopharmaceuticals' perifosine, Merck's Zolinza and Novartis's panobinostat."  

According to the report, most hematologist-oncologists in the EU5 consider patients who are relapsed from or refractory to Velcade to be candidates for carfilzomib in combination with Revlimid.

The report also finds that surveyed payers in both Germany and Spain are questioning how long automatic reimbursement of drugs that have been approved by the European Medicines Agency can last. While several countries have imposed mandatory price cuts on pharmaceuticals, or will do so imminently, the uncertain future of automatic reimbursement policies may have an even more significant market impact than mandatory price cuts.

"Interviewed payers have warned that the days of automatic reimbursement of high-cost targeted cancer therapies may be numbered, particularly when multiple new drugs become available for an indication like myeloma," Dr. Merron said.

The report is based on a survey of 251 hematologist-oncologists from Germany (52), France (50), Italy (49), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
2. Luminex Donates Companys First MAGPIX Multiplexing System to Papua New Guinea Institute of Medical Research
3. Fertility Drugs Contribute Heavily to Multiple Births
4. Clinical Benefits of Electronic Brachytherapy From Xoft Substantiated for the Treatment of Multiple Cancers
5. Volcano Announces Plans to Introduce Multiple New Products at EuroPCR 2010
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Fortis Hospitals Puts 27 Year Old Nigerian Back on her Feet After Multiple Joint Replacement Surgery
8. SRI International Researchers Present Promising New Therapeutic for the Treatment of Multiple Myeloma
9. Multiple Chemical Sensitivities Are Real
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):